Showing results (31-40 of 173) with videos related to

Sort By:
Pageof 18
Pharmaceutics|March 28, 2024
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid LeukemiaSara Galimberti, Elisabetta Abruzzese, Giacomo Luci, et al.
Cancer|August 26, 2010
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patientsPier Luigi Zinzani, Alessandro Broccoli, Vittorio Stefoni, et al.
Journal of Clinical Medicine|January 11, 2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaAlessandro Costa, Elisabetta Abruzzese, Roberto Latagliata, et al.
Cancer|May 16, 2007
Characterization of Ph-negative abnormal clones emerging during imatinib therapyElisabetta Abruzzese, Alessandro Gozzetti, Sara Galimberti, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 16, 2020
NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the LiteratureGianfranco Catalano, Pasquale Niscola, Cristina Banella, et al.
Haematologica|August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemiaTimothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Leukemia Research|August 26, 2017
HLA-G molecules and clinical outcome in Chronic Myeloid LeukemiaGiovanni Caocci, Marianna Greco, Marcella Arras, et al.
Experimental Hematology|March 12, 2011
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cellsGabriella Marfe, Carla Di Stefano, Alessandra Gambacurta, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Chemotherapy|December 22, 2022
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic TransplantFulvia Fanelli, Stefan Hohaus, Maria Cantonetti, et al.
Pageof 18